NM_058195.4:c.193+10224A>G

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_058195.4(CDKN2A):​c.193+10224A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.102 in 152,084 control chromosomes in the GnomAD database, including 977 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.10 ( 977 hom., cov: 32)

Consequence

CDKN2A
NM_058195.4 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: -0.410

Publications

19 publications found
Variant links:
Genes affected
CDKN2A (HGNC:1787): (cyclin dependent kinase inhibitor 2A) This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
CDKN2A Gene-Disease associations (from GenCC):
  • melanoma, cutaneous malignant, susceptibility to, 2
    Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
  • melanoma-pancreatic cancer syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • familial atypical multiple mole melanoma syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • melanoma and neural system tumor syndrome
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.68).
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.135 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CDKN2ANM_058195.4 linkc.193+10224A>G intron_variant Intron 1 of 2 ENST00000579755.2 NP_478102.2 Q8N726-1
LOC124902130XR_007061436.1 linkn.8709A>G non_coding_transcript_exon_variant Exon 2 of 2
CDKN2ANM_001363763.2 linkc.-4+10906A>G intron_variant Intron 1 of 2 NP_001350692.1
CDKN2AXM_047422597.1 linkc.-4+10632A>G intron_variant Intron 1 of 2 XP_047278553.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CDKN2AENST00000579755.2 linkc.193+10224A>G intron_variant Intron 1 of 2 1 NM_058195.4 ENSP00000462950.1 Q8N726-1

Frequencies

GnomAD3 genomes
AF:
0.102
AC:
15456
AN:
151966
Hom.:
976
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0574
Gnomad AMI
AF:
0.276
Gnomad AMR
AF:
0.0981
Gnomad ASJ
AF:
0.141
Gnomad EAS
AF:
0.000769
Gnomad SAS
AF:
0.0348
Gnomad FIN
AF:
0.100
Gnomad MID
AF:
0.127
Gnomad NFE
AF:
0.137
Gnomad OTH
AF:
0.125
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.102
AC:
15465
AN:
152084
Hom.:
977
Cov.:
32
AF XY:
0.0980
AC XY:
7288
AN XY:
74368
show subpopulations
African (AFR)
AF:
0.0573
AC:
2381
AN:
41554
American (AMR)
AF:
0.0981
AC:
1500
AN:
15284
Ashkenazi Jewish (ASJ)
AF:
0.141
AC:
488
AN:
3464
East Asian (EAS)
AF:
0.000771
AC:
4
AN:
5188
South Asian (SAS)
AF:
0.0344
AC:
166
AN:
4826
European-Finnish (FIN)
AF:
0.100
AC:
1060
AN:
10604
Middle Eastern (MID)
AF:
0.136
AC:
40
AN:
294
European-Non Finnish (NFE)
AF:
0.137
AC:
9304
AN:
67854
Other (OTH)
AF:
0.129
AC:
271
AN:
2106
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
699
1399
2098
2798
3497
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
172
344
516
688
860
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.113
Hom.:
228
Bravo
AF:
0.103
Asia WGS
AF:
0.0440
AC:
154
AN:
3478

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.68
CADD
Benign
8.0
DANN
Benign
0.91
PhyloP100
-0.41
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs3731222; hg19: chr9-21983914; API